



EOS imaging Expands Market Presence in South East Asian with First Vietnam Installation

Vietnam's Largest Private Radiologic Center Selects EOS imaging for Low Dose 2D/3D Imaging Services

Paris, October 6, 2014 - EOS imaging (Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, today announces the Company's continued growth in the South East Asian market with the installation of an EOS® imaging system at the Medic Medical Center (MMC) in Ho Chi Minh City. MMC is the largest radiologic center and medical clinic in Vietnam.

MMC is Vietnam's most active medical facility in terms of patient volume, providing service to more than 1,000 patients per day, and offers a wide range of specialized services, such as pediatrics, endocrinology, cardiology and neurology. MMC's network of facilities provides medical services in numerous provinces throughout the country but also in Laos and Cambodia.

Dr. Phan Thanh Hai, Director of the Medic Medical Center at Ho Chi Minh City, said, *"As one of the largest medical centers in Vietnam, we must continually seek out proven technologies that will help provide our physicians with the best diagnostic information and our patients with the best treatment outcomes. Our decision to add the EOS system's low dose 2D/3D imaging satisfies both of those objectives and enables our hospital to continue operating as one of Vietnam's premier medical facilities."*

The EOS system provides full-body images of patients in a natural functional position in both 2D and 3D with 50% to 85% less dose than digital radiology and 95% less dose than basic CT scans, in accordance with the ALARA (As Low As Reasonably Achievable) principle of radiation reduction.

Marie Meynadier, CEO of EOS imaging, said, *"EOS imaging is proud of our continued adoption throughout the South East Asian market with an installation at the Medic Medical Center, which is home to Vietnam's premier radiologic center. MMC's decision to become the first in South East Asia to adopt EOS for 2D/3D orthopaedic imaging demonstrates the level of trust and credibility we continue to establish throughout the entire region."*

For further information about the Company or EOS®, the first full body, low dose 2D/3D imaging system, please visit <http://www.eos-imaging.com/>.

About EOS imaging:

EOS imaging designs, develops, and markets EOS®, a revolutionary and patented medical imaging system, based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Company is authorized to market the system in 33 countries, including the United States (FDA), Japan, Canada, Australia and the European Union (EU). Backed by an installed base of more than 90 sites and by more than 500,000 imaging sessions, EOS® benefits from worldwide recognition within the global medical community. As of December 31, 2013 the Group posted 2013 consolidated revenue of €15.2 million and employed 106 people including an R&D team of 38 engineers. The Group is based in Paris and holds four subsidiaries in Besançon (France), Cambridge (Massachusetts), in Montreal (Canada) and Frankfurt (Germany), and offices in Singapore.



EOS imaging is listed on Compartment C of Euronext Paris

ISIN: FR0011191766 – Ticker: EOSI

Next press release: revenue for the 3rd quarter of 2014, on October 22, 2014 (after market).

EOSI
LISTED
EURONEXT



Contacts:

Anne Renevot

CFO

Ph: +33 (0)1 55 25 61 24

investors@eos-imaging.com

NewCap

Financial communication and investor relations

Sophie Boulila / Pierre Laurent

Ph: +33 (0)1 44 71 94 91 - eosimaging@newcap.fr

The Ruth Group (US)

Press relations / Calvin Allen

Ph: 646-536-7002

callen@theruthgroup.com

EOSI
LISTED
EURONEXT

